References
- Storm G , ten Kate MT , Working PK , Bakker-Woudenberg A. Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system. Clin Cancer Res 1998;4:111–5.
- Szebeni J , Baranyi L , Savay S , et al . The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®). J Liposome Res 2000;10:467–81.
- Barenholz Y . Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release 2012;160:117–34.
- Barenholz Y. 2012. Doxil – the first FDA-approved nano-drug: from an idea to product. In: Peer D , ed. Handbook of harnessing biomaterials in nanomedicine. Singapore: Pan Standford Publishing Pte. Ltd.; 2012:335–98.
- Lorusso D , Di Stefano A , Carone V , et al . Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol. 2007;18:1159–64.
- Szebeni J , Muggia F , Gabizon A , Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011;63:1020–30.
- Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 2014;61:163–73.
- Szebeni J , Storm G. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs. Biochem Biphys Res Commun 2015;468:490–7.
- Szebeni J , Fishbane S , Hedenus M , et al . Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol 2015;172:5025–36.
- Szebeni J , Muggia F , Barenholz Y. Case study: complement activation related hypersensitivity reactions to PEGylated liposomal doxorubicin – experimental and clinical evidence, mechanisms and approaches to inhibition. In: Dobrovolskaia M , McNeil SE , eds. Handbook of immunological properties of engineered nanomaterials, 2nd ed. Hackensack (NJ), Oxon (UK), Singapore: World Scientific, Publishing Co, Inc. Frontiers in Nanobiomedical Research; 2015: 331–61.
- Szebeni JP , Bedőcs R , Urbanics R , et al . Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. J Contr Rel 2012;160:382–7.
- Doxil, Package Label. www.Doxil.com; 2016.
- Gabizon A , Tzemach D , Mak L , et al . Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal Doxorubicin (DOXIL) in murine models. J Drug Target 2002;10:539–48.
- Gabizon A, R , Isacson O , Rosengarten D , et al . Sapir, An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 2007;61:695–702.
- Baranyi L , Szebeni J , Sávay S , et al . Complement-dependent shock and tissue damage induced by intravenous injection of cholesterol-enriched liposomes in rats. J Appl Res Clin Exp Ther 2003;3:3–20.
- Dézsi L , Fülöp T , Mészáros T , et al . Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses. J Contr Release 2014;195:2–10.
- Szebeni J , Bedőcs P , Csukas D , et al . A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv Drug Deliv Rev 2012;64:1706–16.
- Alberts DS , Liu Y , Wilczynski SP , et al . Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (South West Oncology group protocol SO200). Gynecol Oncol 2008;108:90–4.